nach oben

Erschienen in:

01.03.2011 | Original Article

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs

verfasst von: Dirk Heshe, Stephanie Hoogestraat, Christine Brauckmann, Uwe Karst, Joachim Boos, Claudia Lanvers-Kaminsky

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists’, clinicians’ but also patients’ interests and prompted us to further evaluate DCA effects against paediatric malignancies.

Methods

The effects of DCA on mitochondrial membrane potential (ΔΨm), cell viability and induction of apoptosis were evaluated in paediatric tumour cell lines and the non-malignant cell line HEK293. In addition, combinations of DCA with the standard anticancer drugs cisplatin, doxorubicin, and temozolomide were tested and intra- and extra-cellular platinum species analysed.

Results

DCA selectively induced phosphatidylserine externalisation and reduced ΔΨm in paediatric tumour cells compared to HEK293 cells, but DCA concentrations ≤10 mmol/L only moderately inhibited the growth of 18 paediatric tumour cell lines. DCA neither influenced the in vitro stability of cisplatin nor the cellular cisplatin uptake, but it abrogated the cytotoxicity of cisplatin in 7 out of 10 cell lines. DCA also affected the cytotoxicity of doxorubicin but did not influence the cytotoxicity of temozolomide. Despite phosphatidylserine externalisation, DCA failed to activate caspase 3/7 and, moreover, suppressed caspase 3/7 activation by cisplatin and doxorubicin.

Conclusions

Our results indicate that apart from the intriguing effects of DCA on the glucose metabolism of cancer cells, the use of DCA for cancer treatment has to be evaluated carefully. Moreover, compassionate use of the orally available drug by patients with cancer themselves without medical supervision is strongly discouraged at present.

Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed

Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899CrossRefPubMed

Samudio I, Fiegl M, Andreeff M (2009) Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69:2163–2166CrossRefPubMed

Stacpoole PW (1989) The pharmacology of dichloroacetate. Metabolism 38:1124–1144CrossRefPubMed

Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM (1998) Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329:191–196PubMed

Bonnet S, Archer SL, Allalunis-Turner J et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51CrossRefPubMed

Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I (2008) Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109:394–402CrossRefPubMed

Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ (2008) Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68:1223–1231CrossRefPubMed

Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC (2009) Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120:253–260CrossRefPubMed

10.

Chen Y, Cairns R, Papandreou I, Koong A, Denko NC (2009) Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One 4:e7033CrossRefPubMed

11.

Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Haung P (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613–621CrossRefPubMed

12.

Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989–994CrossRefPubMed

13.

Stacpoole PW, Nagaraja NV, Hutson AD (2003) Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43:683–691PubMed

14.

Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW, Shuster JJ (2008) Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 121:1223–1228CrossRef

15.

Mori M, Yamagata T, Goto T, Saito S, Momoi MY (2004) Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 26:453–458CrossRefPubMed

16.

Pearson H (2007) Cancer patients opt for unapproved drug. Nature 446:474–475CrossRefPubMed

17.

Chen LB (1988) Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155–181CrossRefPubMed

18.

Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, Ruf J, Furth C, Stöver B, Hautzel H, Henze G, Amthauer H (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25:5435–5441CrossRefPubMed

19.

Chen QR, Song YK, Yu LR, Wei JS, Chung JY, Hewitt SM, Veenstra TD, Khan J (2010) Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J Proteome Res 9:373–382CrossRefPubMed

20.

Wellmann S, Guschmann M, Griethe W, Eckert C, von Stackelberg A, Lottaz C, Moderegger E, Einsiedel HG, Eckardt KU, Henze G, Seeger K (2004) Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18:926–933CrossRefPubMed

21.

Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML (2009) Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113:2014–2021CrossRefPubMed

22.

Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ (2008) Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283:28106–28114CrossRefPubMed

23.

Stacpoole PW, Kurtz TL, Han Z, Langaee T (2008) Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 60:1478–1487CrossRefPubMed

24.

Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, Haas RH (2004) Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab 83:138–149CrossRefPubMed

25.

Dhar S, Lippard SJ (2009) Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci USA 106:22199–22204CrossRefPubMed

26.

Vyssokikh MY, Brdiczka D (2003) The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim Pol 50:389–404PubMed

27.

Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12:5817–5825CrossRefPubMed

28.

Tokarska-Schlattner M, Wallimann T, Schlattner U (2006) Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 329:657–668CrossRefPubMed

Titel: Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs
verfasst von: Dirk Heshe
Stephanie Hoogestraat
Christine Brauckmann
Uwe Karst
Joachim Boos
Claudia Lanvers-Kaminsky
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1361-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs